1. Home /
  2. Drug Approvals

Drug Approvals

Chart of the Day, Part 1: Canopy Growth Could Be Key to Constellation Long Term

Analysts have noted that the weed leader's momentum is set to burn higher moving forward.

Real Money Goes Behind the Scenes of the Budding Cannabis Industry

In the interest of due diligence, we went and took a close look at the ground floor of the newest investment craze.

Pfizer's Oncology Offerings Present Opportunity for Long-Term Stock Growth

The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.

Pfizer Stock Slides Slightly as Drug-Maker Prepares Price Increases

Pfizer may have poked the bear.

Eli Lilly's Elanco Offload Offers Acquisition Flexibility

Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.

Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken

Once the safest stocks in the book, the big-cap drug companies are now toxic.

Be Ready to Ride the Dividend on Gilead Sciences

There are no catalysts to drive the stock price higher, so for now, Gilead is simply a cheap stock with a nice dividend.

Names to Watch Amid Biotech's Nascent Rally

Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.

3 Small Biotechs Turn on the Revenue Jets

BioDelivery Sciences, Neos Therapeutics and Invitae Corp. are delivering big increases in sales.

How to Play Biotech 'Sell the News' Pattern

Patient investors can profit from small-cap biotech stocks that often slide once positive news comes out.